Parsing Geron's Stem Cell Foray: A Nature Journal Commentary
Why did Geron "fail" in its much ballyhooed pursuit of the first-ever human embryonic stem cell therapy?
Christopher Scott, senior research scholar at Stanford, and Brady Huggett, business editor of the journal Nature, took a crack at answering that question in a commentary in the June edition of Nature.
Following the sudden abandonment last fall by Geron…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.